{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:19:08Z","timestamp":1787750348063,"version":"build-2784847793"},"reference-count":97,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>Among the various treatments for type 2 diabetes during the initial period, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors have been considered together as agents with separate cardiometabolic benefits, given their limited glucose-lowering effects. GLP-1 RAs are reported to inhibit atherosclerosis through several physiological processes, including increased blood flow in endothelial tissues, decreased inflammation, increased antioxidant levels, and improved lipid profile. There is a similar situation with SGLT2 inhibitors, and the explanation for this is different yet complementary, as these drugs cause a decrease in both cardiac preload and afterload and, at the same time, increase vascular permeability, diuresis, and more efficient energy usage by the heart. Thus, they have been affirmed by extensive clinical trials, which show that, although these drugs may harm patients, they do not result in significant cardiovascular events, have a lower treatment rate for heart defects, and are associated with a longer time before the patient\u2019s renal function deteriorates. This translates into a continuing shift toward the dominion in terms of cardiometabolic protection \u2013 a strategy that is receiving strong backing from the majority of clinical guidelines across the world.<\/jats:p>","DOI":"10.4103\/ijp.ijp_1384_25","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T18:00:09Z","timestamp":1782410409000},"page":"293-306","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Combined use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular protection"],"prefix":"10.4103","volume":"58","author":[{"given":"Soumya Shanta","family":"Mohanty","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, R R College of Pharmacy, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. R.","family":"Selvammathy","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, R R College of Pharmacy, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hindustan Abdul","family":"Ahad","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, R R College of Pharmacy, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edukulla Satheesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, R R College of Pharmacy, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"R1-20260626","doi-asserted-by":"crossref","first-page":"6678","DOI":"10.3390\/jcm14186678","article-title":"Rethinking the diabetes-cardiovascular disease continuum: Toward integrated care","volume":"14","author":"Caturano","year":"2025","journal-title":"J Clin Med"},{"key":"R2-20260626","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/5584_2020_494","article-title":"GLP-1 receptor agonists and SGLT2 inhibitors for the treatment of type 2 diabetes: New insights and opportunities for cardiovascular protection","volume":"4","author":"Bertoccini","year":"2020","journal-title":"Diabetes Res Clin Practice"},{"key":"R3-20260626","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/joim.12890","article-title":"Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: Focus on SGLT-2 inhibitors and GLP-1 receptor agonists","volume":"286","author":"Bonaventura","year":"2019","journal-title":"J Intern Med"},{"key":"R4-20260626","doi-asserted-by":"crossref","first-page":"1663787","DOI":"10.3389\/fendo.2025.1663787","article-title":"A decade of progress in type 2 diabetes and cardiovascular disease: Advances in SGLT2 inhibitors and GLP-1 receptor agonists \u2013 A comprehensive review","volume":"16","author":"Aristiz\u00e1bal-Colorado","year":"2025","journal-title":"Front Endocrinol"},{"key":"R5-20260626","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s13300-019-00680-5","article-title":"Cardiorenal protection: Potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes","volume":"10","author":"Nagahisa","year":"2019","journal-title":"Diabetes Ther"},{"key":"R6-20260626","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/cells14050387","article-title":"Insights into the roles of GLP-1, DPP-4, and SGLT2 at the crossroads of cardiovascular, renal, and metabolic pathophysiology","volume":"14","author":"Gaggini","year":"2025","journal-title":"Cells"},{"key":"R7-20260626","first-page":"288","article-title":"Gastrointestinal incretins-glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) beyond pleiotropic physiological effects are involved in pathophysiology of atherosclerosis and coronary artery disease-state of the art","volume":"11","author":"Jonik","year":"2022","journal-title":"Biology (Basel)"},{"key":"R8-20260626","doi-asserted-by":"crossref","first-page":"e240046","DOI":"10.1530\/JOE-24-0046","article-title":"GLP-1 receptor agonist-based therapies and cardiovascular risk: A review of mechanisms","volume":"263","author":"Mullur","year":"2024","journal-title":"J Endocrinol"},{"key":"R9-20260626","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.7326\/M21-0893","article-title":"Sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease","volume":"174","author":"Patorno","year":"2021","journal-title":"Ann Intern Med"},{"key":"R10-20260626","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3390\/biom15101403","article-title":"GLP-1 receptor agonists in heart failure","volume":"15","author":"Rahmani","year":"2025","journal-title":"Biomolecules"},{"key":"R11-20260626","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.3390\/biomedicines13112595","article-title":"Complementary yet distinct roles of GLP-1 receptor agonists and SGLT2 inhibitors in cardiovascular risk reduction","volume":"13","author":"Homor\u00f3di","year":"2025","journal-title":"Biomedicines"},{"key":"R12-20260626","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/dom.16107","article-title":"SGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and\/or obesity: A systematic review and network meta-analysis","volume":"27","author":"Bao","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"R13-20260626","doi-asserted-by":"crossref","first-page":"154937","DOI":"10.1016\/j.metabol.2021.154937","article-title":"SGLT-2 inhibitors as cardio-renal protective agents","volume":"127","author":"Caruso","year":"2022","journal-title":"Metabolism"},{"key":"R14-20260626","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s11883-022-01062-2","article-title":"GLP-1 agonist to treat obesity and prevent cardiovascular disease: What have we achieved so far?","volume":"24","author":"Pedrosa","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"R15-20260626","doi-asserted-by":"crossref","first-page":"7184","DOI":"10.3390\/ijms24087184","article-title":"The effects of cardioprotective antidiabetic therapy on microbiota in patients with type 2 diabetes mellitus-a systematic review","volume":"24","author":"Bica","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R16-20260626","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4330\/wjc.v14.i6.329","article-title":"Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes","volume":"14","author":"Singh","year":"2022","journal-title":"World J Cardiol"},{"key":"R17-20260626","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"R18-20260626","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/metabo12020183","article-title":"Cardiovascular and renal effectiveness of GLP-1 receptor agonists versus other glucose-lowering drugs in type 2 diabetes: A systematic review and meta-analysis of real-world studies","volume":"12","author":"Caruso","year":"2022","journal-title":"Metabolites"},{"key":"R19-20260626","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12933-023-01800-z","article-title":"Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: A real-world study","volume":"22","author":"Piccini","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"R20-20260626","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12933-025-02778-6","article-title":"Refining the link between obesity and heart failure: Insights from GLP-1 receptor agonist trials and studies adopting direct adiposity measures","volume":"24","author":"Pugliese","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"R21-20260626","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/antiox14060701","article-title":"Antioxidant effects of SGLT2 inhibitors on cardiovascular-kidney-metabolic (CKM) syndrome","volume":"14","author":"Guerrero-Mauvecin","year":"2025","journal-title":"Antioxidants (Basel)"},{"key":"R22-20260626","doi-asserted-by":"crossref","first-page":"1349069","DOI":"10.3389\/fphar.2024.1349069","article-title":"Emerging role of antidiabetic drugs in cardiorenal protection","volume":"15","author":"Fu","year":"2024","journal-title":"Front Pharmacol"},{"key":"R23-20260626","doi-asserted-by":"crossref","first-page":"2575921","DOI":"10.1080\/0886022X.2025.2575921","article-title":"Chronic cardiorenal syndrome: Cardio-renal protective effect of SGLT2i","volume":"47","author":"Zhu","year":"2025","journal-title":"Ren Fail"},{"key":"R24-20260626","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/01410768231198442","article-title":"Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"117","author":"Kunutsor","year":"2024","journal-title":"J R Soc Med"},{"key":"R25-20260626","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1089\/met.2023.0227","article-title":"A new hope on the horizon for kidney and cardiovascular protection with SGLT2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor antagonists in type 2 diabetic and chronic kidney disease patients","volume":"22","author":"Spasovski","year":"2024","journal-title":"Metab Syndr Relat Disord"},{"key":"R26-20260626","first-page":"9032378","article-title":"SGLT2i and GLP-1RA in cardiometabolic and renal diseases: From glycemic control to adipose tissue inflammation and senescence","author":"D'Marco","year":"2021","journal-title":"J Diabetes Res 2021"},{"key":"R27-20260626","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: Established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"key":"R28-20260626","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2337\/dc19-1943","article-title":"Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013-2018","volume":"43","author":"Dave","year":"2020","journal-title":"Diabetes Care"},{"key":"R29-20260626","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12933-021-01400-9","article-title":"GLP-1 receptor agonists versus SGLT-2 inhibitors: The gap seems to be leveling off","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"R30-20260626","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: Mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int J Clin Pract"},{"key":"R31-20260626","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1677\/erc.0.0070017","article-title":"Similarities and distinctions in the mode of action of different classes of antioestrogens","volume":"7","author":"Wakeling","year":"2000","journal-title":"Endocr Relat Cancer"},{"key":"R32-20260626","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00417-023-06236-5","article-title":"Effects of newer-generation anti-diabetics on diabetic retinopathy: A critical review","volume":"262","author":"Ntentakis","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R33-20260626","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1213\/ANE.0000000000006791","article-title":"Society for ambulatory anesthesia updated consensus statement on perioperative blood glucose management in adult patients with diabetes mellitus undergoing ambulatory surgery","volume":"139","author":"Rajan","year":"2024","journal-title":"Anesth Analg"},{"key":"R34-20260626","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1253\/circj.66.529","article-title":"Clinical importance of endothelial function in arteriosclerosis and ischemic heart disease","volume":"66","author":"Egashira","year":"2002","journal-title":"Circ J"},{"key":"R35-20260626","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial cell dysfunction and the pathobiology of atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ Res"},{"key":"R36-20260626","first-page":"168","article-title":"Organ transplantation, pros, cons, and illustrations: A basic awareness to the public","volume":"4","author":"Ahad","year":"2021","journal-title":"Abasyn J Life Sci"},{"key":"R37-20260626","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.carpath.2012.06.006","article-title":"Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis","volume":"22","author":"Gimbrone","year":"2013","journal-title":"Cardiovasc Pathol"},{"key":"R38-20260626","doi-asserted-by":"crossref","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"R39-20260626","doi-asserted-by":"crossref","first-page":"1257988","DOI":"10.3389\/fimmu.2023.1257988","article-title":"Research progress of NF-\u03baB signaling pathway and thrombosis","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"R40-20260626","doi-asserted-by":"crossref","first-page":"10822","DOI":"10.3390\/ijms221910822","article-title":"Inflammation and oxidative stress in diabetic kidney disease: The targets for SGLT2 inhibitors and GLP-1 receptor agonists","volume":"22","author":"Winiarska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R41-20260626","doi-asserted-by":"crossref","first-page":"113222","DOI":"10.1016\/j.intimp.2024.113222","article-title":"GLP-1 analogue liraglutide attenuates CIH-induced cognitive deficits by inhibiting oxidative stress, neuroinflammation, and apoptosis via the Nrf2\/HO-1 and MAPK\/NF-\u03baB signaling pathways","volume":"142","author":"Lv","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R42-20260626","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40620-020-00749-6","article-title":"Targeting oxidative stress and anti-oxidant defence in diabetic kidney disease","volume":"33","author":"\u00d8stergaard","year":"2020","journal-title":"J Nephrol"},{"key":"R43-20260626","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s10787-022-00978-0","article-title":"Anti-inflammatory potential of liraglutide, a glucagon-like peptide-1 receptor agonist, in rats with peripheral acute inflammation","volume":"30","author":"Mert","year":"2022","journal-title":"Inflammopharmacology"},{"key":"R44-20260626","doi-asserted-by":"crossref","first-page":"108906","DOI":"10.1016\/j.jdiacomp.2024.108906","article-title":"Exploring the antioxidant properties of semaglutide: A comprehensive review","volume":"38","author":"Yaribeygi","year":"2024","journal-title":"J Diabetes Complications"},{"key":"R45-20260626","doi-asserted-by":"crossref","first-page":"1438926","DOI":"10.3389\/fphar.2024.1438926","article-title":"Daphnetin modulates GLP-1R to alleviate cognitive dysfunction in diabetes: Implications for inflammation and oxidative stress","volume":"15","author":"Liang","year":"2024","journal-title":"Front Pharmacol"},{"key":"R46-20260626","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2337\/dc19-2251","article-title":"Cardiovascular risk reduction with liraglutide: An exploratory mediation analysis of the LEADER trial","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"R47-20260626","first-page":"216","article-title":"Potential anti-inflammatory role of anti-diabetic agents","volume":"24","author":"Kumar","year":"2022","journal-title":"JK Sci J Med Educ Res"},{"key":"R48-20260626","doi-asserted-by":"crossref","first-page":"645566","DOI":"10.3389\/fendo.2021.645566","article-title":"Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: Findings from sustain 6 and pioneer 6","volume":"12","author":"Nauck","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R49-20260626","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.ekir.2024.04.028","article-title":"Effects of once-weekly semaglutide on kidney disease outcomes by KDIGO risk category in the SUSTAIN 6 trial","volume":"9","author":"Tuttle","year":"2024","journal-title":"Kidney Int Rep"},{"key":"R50-20260626","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"R51-20260626","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: An exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"R52-20260626","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(19)30423-1","article-title":"The effect of dulaglutide on stroke: An exploratory analysis of the REWIND trial","volume":"8","author":"Gerstein","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R53-20260626","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/ehjcvp\/pvae006","article-title":"Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the harmony outcomes trial","volume":"10","author":"Krychtiuk","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R54-20260626","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.3390\/jcm13164674","article-title":"Cardiovascular protective properties of GLP-1 receptor agonists: More than just diabetic and weight loss drugs","volume":"13","author":"Le","year":"2024","journal-title":"J Clin Med"},{"key":"R55-20260626","first-page":"p. 18","article-title":"Is Cardioprotection with GLP-1 Receptor Agonists A Class Effect?","author":"Ryd\u00e9n","year":"2021","journal-title":"Great Clarendon Street, Oxford"},{"key":"R56-20260626","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2337\/dc24-1533","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: A systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"key":"R57-20260626","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: Pooled analysis of sustain 6 and leader","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"R58-20260626","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1111\/dom.16424","article-title":"Glucagon-like peptide-1 receptor agonists lower risk of cardiovascular and non-cardiovascular mortality: A meta-analysis of eleven cardiovascular outcome trials","volume":"27","author":"Kang","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"R59-20260626","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.amjcard.2021.05.043","article-title":"Usefulness of glucagon-like peptide-1 receptor agonists to reduce adverse cardiovascular disease events in patients with type 2 diabetes mellitus","volume":"154","author":"Grewal","year":"2021","journal-title":"Am J Cardiol"},{"key":"R60-20260626","doi-asserted-by":"crossref","first-page":"e70004","DOI":"10.1002\/dmrr.70004","article-title":"GLP-1: A prospective guardian for comprehensive myocardial perfusion","volume":"40","author":"Li","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"R61-20260626","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5853\/jos.2025.00584","article-title":"Glucagon-like peptide-1 receptor agonists in the prevention of ischemic stroke: Therapeutic potential and mechanisms","volume":"27","author":"Lin","year":"2025","journal-title":"J Stroke"},{"key":"R62-20260626","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2527\/jas.2006-298","article-title":"Heart rate measurements as an index of energy expenditure and energy balance in ruminants: A review","volume":"85","author":"Brosh","year":"2007","journal-title":"J Anim Sci"},{"key":"R63-20260626","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/cvr\/cvz045","article-title":"Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency","volume":"115","author":"Ho","year":"2019","journal-title":"Cardiovasc Res"},{"key":"R64-20260626","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.healun.2017.06.018","article-title":"Effects of pre-load variations on hemodynamic parameters with a pulsatile autoregulated artificial heart during the early post-operative period","volume":"37","author":"Bizouarn","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"R65-20260626","doi-asserted-by":"crossref","first-page":"1050274","DOI":"10.3389\/fonc.2022.1050274","article-title":"The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"R66-20260626","doi-asserted-by":"crossref","first-page":"14083","DOI":"10.1096\/fj.202000975R","article-title":"A molecular basis for the anti-inflammatory and anti-fibrosis properties of cannabidiol","volume":"34","author":"Sunda","year":"2020","journal-title":"FASEB J"},{"key":"R67-20260626","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(20)30344-2","article-title":"Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: A secondary analysis of the Empa-Reg outcome trial","volume":"8","author":"McGuire","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R68-20260626","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jchf.2021.03.003","article-title":"Patient phenotypes and SGLT-2 inhibition in type 2 diabetes: Insights from the EMPA-REG outcome trial","volume":"9","author":"Sharma","year":"2021","journal-title":"JACC Heart Fail"},{"key":"R69-20260626","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1681\/ASN.2019010064","article-title":"Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: Data from the CANVAS program","volume":"30","author":"Neuen","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"R70-20260626","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: An analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R71-20260626","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ejhf.1548","article-title":"The dapagliflozin and prevention of adverse-outcomes in heart failure (DAPA-HF) trial: Baseline characteristics","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"R72-20260626","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: Results of Dapa-Hf","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"R73-20260626","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/10408363.2021.1993439","article-title":"Cardiovascular benefit of SGLT2 inhibitors","volume":"59","author":"Mohebi","year":"2022","journal-title":"Crit Rev Clin Lab Sci"},{"key":"R74-20260626","first-page":"262","article-title":"Cardiovascular benefits of SGLT2 inhibitors in patients with heart failure: A meta-analysis of small and large randomized controlled trials","volume":"11","author":"Shoar","year":"2021","journal-title":"Am J Cardiovasc Dis"},{"key":"R75-20260626","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"R76-20260626","doi-asserted-by":"crossref","first-page":"1216160","DOI":"10.3389\/fendo.2023.1216160","article-title":"Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: A systematic review and network meta-analysis of randomized controlled trials","volume":"14","author":"Kongmalai","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R77-20260626","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.3390\/ijms22115863","article-title":"Impact of SGLT2 inhibitors on heart failure: From pathophysiology to clinical effects","volume":"22","author":"Palmiero","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R78-20260626","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijcard.2021.03.077","article-title":"Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials","volume":"332","author":"Li","year":"2021","journal-title":"Int J Cardiol"},{"key":"R79-20260626","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3390\/jcm11061470","article-title":"SGLT2 inhibitors in type 2 diabetes mellitus and heart failure-a concise review","volume":"11","author":"Keller","year":"2022","journal-title":"J Clin Med"},{"key":"R80-20260626","doi-asserted-by":"crossref","first-page":"e009837","DOI":"10.1161\/CIRCHEARTFAILURE.122.009837","article-title":"Dapagliflozin improves heart failure symptoms and physical limitations across the full range of ejection fraction: Pooled patient-level analysis from DEFINE-HF and PRESERVED-HF trials","volume":"16","author":"Nassif","year":"2023","journal-title":"Circ Heart Fail"},{"key":"R81-20260626","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4239\/wjd.v12.i5.514","article-title":"Euglycemic diabetic ketoacidosis: A missed diagnosis","volume":"12","author":"Nasa","year":"2021","journal-title":"World J Diabetes"},{"key":"R82-20260626","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.3390\/diagnostics13152602","article-title":"Diabetic ketoacidosis in children and adolescents;diagnostic and therapeutic pitfalls","volume":"13","author":"Kostopoulou","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R83-20260626","doi-asserted-by":"crossref","first-page":"l1114","DOI":"10.1136\/bmj.l1114","article-title":"Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome: Review of acute decompensated diabetes in adult patients","volume":"365","author":"Karslioglu French","year":"2019","journal-title":"BMJ"},{"key":"R84-20260626","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"R85-20260626","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-018-0800-2","article-title":"GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data","volume":"17","author":"Sposito","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"R86-20260626","first-page":"p. 304","article-title":"Excessive thirst hunger, and urination in diabetes","author":"Gregory","year":"2023","journal-title":"In: Introduction to Clinical Pharmacology: From Symptoms to Treatment. Newcastle upon Tyne"},{"key":"R87-20260626","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3390\/biomedicines13030728","article-title":"Targeting diabetic atherosclerosis: The role of GLP-1 receptor agonists, SGLT2 inhibitors, and nonsteroidal mineralocorticoid receptor antagonists in vascular protection and disease modulation","volume":"13","author":"Rroji","year":"2025","journal-title":"Biomedicines"},{"key":"R88-20260626","doi-asserted-by":"crossref","first-page":"112452","DOI":"10.1016\/j.diabres.2025.112452","article-title":"Effects of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on CRT response and clinical outcomes in in type 2 diabetes mellitus patients receiving chronic anti-diabetic medications: A multicenter observational study","volume":"228","author":"Sardu","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"R89-20260626","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13098-025-01635-6","article-title":"Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Mousavi","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"R90-20260626","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jacc.2023.05.048","article-title":"GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes","volume":"82","author":"Neves","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R91-20260626","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s11095-024-03771-6","article-title":"Impact of manufacturing process and compounding on properties and quality of follow-On GLP-1 polypeptide drugs","volume":"41","author":"Hach","year":"2024","journal-title":"Pharm Res"},{"key":"R92-20260626","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11095-020-02817-9","article-title":"Influence of production process and scale on quality of polypeptide drugs: A case study on GLP-1 analogs","volume":"37","author":"Staby","year":"2020","journal-title":"Pharm Res"},{"key":"R93-20260626","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/eurjpc\/zwac315","article-title":"Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA\/EASD consensus report in a national population of patients with type 2 diabetes","volume":"30","author":"Lim","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"R94-20260626","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.jacc.2022.02.046","article-title":"Guidelines for cardiovascular risk reduction in patients with type 2 diabetes: JACC guideline comparison","volume":"79","author":"Kelsey","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R95-20260626","first-page":"2748","article-title":"Heart failure with preserved ejection fraction therapy: Combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists","author":"Ostrominski","year":"2024","journal-title":"UK: Oxford University Press"},{"key":"R96-20260626","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.2147\/DDDT.S559919","article-title":"The clinical application of GLP-1RAs and GLP-1\/GIP dual receptor agonists based on pharmacological mechanisms: A review","volume":"19","author":"Liu","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"R97-20260626","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/biomedicines12061320","article-title":"New developments in pharmacological treatment of obesity and type 2 diabetes-beyond and within GLP-1 receptor agonists","volume":"12","author":"Sztanek","year":"2024","journal-title":"Biomedicines"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_1384_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:26:25Z","timestamp":1787747185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_1384_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_1384_25","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2025-12-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}